On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 – ...

Lisa Ricciardi, president and CEO of Cognition Therapeutics was recently a guest on Benzinga's All-Access. Cognition ...

Nuvie Bio, a new clinical-stage biopharmaceutical company dedicated to addressing the most pressing unmet medical needs in migraine and related neurological diseases, announced completion of a ...

Geode Capital Management LLC grew its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) by 148.7% in ...

BrainSight AI raised $5 million in pre-series A funding round. With plans to expand in India and pursue FDA certification.

Geode Capital Management LLC lifted its position in Vigil Neuroscience, Inc. (NASDAQ:VIGL – Free Report) by 41.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 226,083 shares of the ...

Patient Enrollment Ongoing in Phase 2 RECONNECT Trial of RE104 in Postpartum Depression (PPD); Topline Data Anticipated Mid-2025Initiation of ...

NYSE:ANRO) Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm ...

Aspen Neuroscience, Inc. has advanced its plans for automating production of ANPD001, including a capacity expansion for autologous manufacturing at its San Diego -based GMP facility.

Iluzanebart is under clinical development by Vigil Neuroscience and currently in Phase I for Unspecified Neurologic Disorders.